Processing

Please wait...

PATENTSCOPE will be unavailable a few hours for maintenance reason on Tuesday 25.01.2022 at 12:00 PM CET
Settings

Settings

Goto Application

1. WO2022002868 - ANTIVIRAL PHARMACEUTICAL COMPOSITION

Publication Number WO/2022/002868
Publication Date 06.01.2022
International Application No. PCT/EP2021/067732
International Filing Date 28.06.2021
IPC
A61K 31/737 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
70Carbohydrates; Sugars; Derivatives thereof
715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
737Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
A61P 31/16 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
31Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
12Antivirals
14for RNA viruses
16for influenza or rhinoviruses
Applicants
  • GSK CONSUMER HEALTHCARE SARL [CH]/[CH]
Inventors
  • LOMBARDI, Maria Stella
Agents
  • GUNDEL, Isabelle
Priority Data
20183323.330.06.2020EP
Publication Language English (en)
Filing Language English (EN)
Designated States
Title
(EN) ANTIVIRAL PHARMACEUTICAL COMPOSITION
(FR) COMPOSITION PHARMACEUTIQUE ANTIVIRALE
Abstract
(EN) Pharmaceutical compositions are described comprising fucoidan for use in a method for the treatment or the prevention, by intranasal administration, of an infection with rhinovirus or respiratory syncytial virus in a human. Particularly, the viral infection is HRV-C15, HRV-A16, or HRV-B14 infection or RSV type A infection. There are also described pharmaceutical compositions comprising fucoidan for use in a method for prevention of rhinovirus spread or respiratory syncytial virus spread in a human population, wherein subjects of the population are tested for infection with HRV-C15, HRV-A16, or HRV-B14 or RSV type A and infected subjects are treated with intranasal administration of the pharmaceutical composition.
(FR) L'invention concerne des compositions pharmaceutiques comprenant du fucoïdane, destinées à être utilisées dans un procédé de traitement ou de prévention, par administration intranasale, d'une infection par un rhinovirus ou un virus respiratoire syncytial chez un être humain. En particulier, l'infection virale est une infection au RVH-C15, RVH-A16 ou RVH-B14 ou une infection au VRS de type A. L'invention concerne également des compositions pharmaceutiques comprenant du fucoïdane, destinées à être utilisées dans un procédé de prévention de la propagation du rhinovirus ou du virus respiratoire syncytial dans une population humaine, des sujets de la population étant testés pour une infection au RVH-C15, RVH-A16 ou RVH-B14 ou une infection au VRS de type A, et les sujets infectés étant traités par administration intranasale de la composition pharmaceutique.
Related patent documents
Latest bibliographic data on file with the International Bureau